AstraZeneca plc

12/08/2021 | Press release | Distributed by Public on 12/08/2021 15:01

Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

Only antibody therapy authorised in US for pre-exposure prophylaxis

Pivotal phase III data showed robust efficacy and long-term protection with one dose in high-risk population